News on TSOI Therapeutic Solutions Internationa
Post# of 208
(Total Views: 361)
Posted On: 06/15/2018 2:21:30 AM
News on TSOI
Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio By Incorporation Of "Universal Cancer Antigen" Into StemVacs Dendritic Cell Platform
GlobeNewswire - Mon Jun 11, 8:00AM CDT
Via OTC PR Wire --Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.
The Company previously filed a patent on technologies covering novel means of stimulating the immune system to kill cancer using naturally made nanoparticles termed "exosomes". The patent whose Mexican rights are licensed to the Pan Am Cancer Treatment Centers covers the production and composition of matter of agents aimed at immunologically eradicating cancer stem cells. In contrast to previous exosome-based cancer therapeutic approaches, the strategy disclosed in the patent involves focusing the immune system to attack the CTCFL protein, which is selectively found on cancer stem cells.
"The CTCFL or BORIS protein represents a unique onco-target in the fight against cancer since it is only found on cancer cells and not healthy tissues. Our strategy possesses the possibility of inducing an immune response that would strike cancer at its very roots, the cancer stem cells," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
"The recently approved Right to Try Law allows for accelerated clinical development of therapeutics that possess Phase I data. We plan to leverage this and other programs to take our scientific discoveries from the bench to the patient's bedside," said Dr. James Veltmeyer, Member of the Company's Scientific Advisory Board.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
About Pan Am Cancer Treatment Center
Pan Am Cancer Treatment Center contact information:
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
https://patents.google.com/patent/US20170143812
Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio By Incorporation Of "Universal Cancer Antigen" Into StemVacs Dendritic Cell Platform
GlobeNewswire - Mon Jun 11, 8:00AM CDT
Via OTC PR Wire --Therapeutics Solutions International, Inc., (OTC Markets:TSOI) announced today initiation of efforts to combine its existing CTCFL "universal cancer antigen", labeled as BRS-001, with its clinical stage StemVacs Dendritic Cell Platform.
The Company previously filed a patent on technologies covering novel means of stimulating the immune system to kill cancer using naturally made nanoparticles termed "exosomes". The patent whose Mexican rights are licensed to the Pan Am Cancer Treatment Centers covers the production and composition of matter of agents aimed at immunologically eradicating cancer stem cells. In contrast to previous exosome-based cancer therapeutic approaches, the strategy disclosed in the patent involves focusing the immune system to attack the CTCFL protein, which is selectively found on cancer stem cells.
"The CTCFL or BORIS protein represents a unique onco-target in the fight against cancer since it is only found on cancer cells and not healthy tissues. Our strategy possesses the possibility of inducing an immune response that would strike cancer at its very roots, the cancer stem cells," said Timothy Dixon, President and CEO of Therapeutic Solutions International.
"The recently approved Right to Try Law allows for accelerated clinical development of therapeutics that possess Phase I data. We plan to leverage this and other programs to take our scientific discoveries from the bench to the patient's bedside," said Dr. James Veltmeyer, Member of the Company's Scientific Advisory Board.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.
About Pan Am Cancer Treatment Center
Pan Am Cancer Treatment Center contact information:
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
https://patents.google.com/patent/US20170143812
(1)
(0)Therapeutic Solutions International Inc (TSOI) Stock Research Links
Louis Pasteur -- chance favours only the prepared mind.
Lecture, University of Lille (7 December 1854)
Lecture, University of Lille (7 December 1854)
Scroll down for more posts ▼